Endosense
Geneva
About Endosense
Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense's TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $100K – $500K
- Total funding: $141.5M
- Funding stage: M&A
- Last round: Series C (Nov 2013)
- Website: endosense.com
- Phone: 41 22 306 19 60
Industries & Categories
Biotechnology, Health Care, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/endosense-3152690 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.